Beyond NSCLC, T-DXd is also approved for HER2-positive or HER2-low breast cancer and advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.